- AsymBio has commenced commercial production at its 130,000 m² Shanghai Fengxian Commercial Manufacturing Base, expanding its global biologics CDMO network.
- The facility provides large-scale capacity across antibodies, bioconjugates and next-generation modalities, supporting development from early clinical phases to commercial supply.
AsymBio has begun commercial production at its Shanghai Fengxian Commercial Manufacturing Base, marking a major expansion of the company’s global contract development and manufacturing (CDMO) capabilities. The 130,000-square-metre site establishes a new strategic hub within AsymBio’s network, supporting biologics programmes from early development through to commercial supply.
The company stated that the launch builds on the foundation established at its Shanghai Jinshan Base and Zhangjiang Center for Biological Technology and Innovation. Designed for flexibility and scalability, the Fengxian facility offers tailored CDMO solutions across all clinical phases, reinforcing the organisation’s commitment to accelerating the commercialisation of innovative therapies.
The site is equipped to support a wide range of biotherapeutic modalities, including antibody-drug conjugates (ADCs), dual-payload ADCs, recombinant proteins and multispecific antibodies. Phase IA of the facility includes single-use bioreactors at 200 L, 500 L and 2,000 L, providing a total drug substance capacity of 66,000 litres, alongside a 20 m² lyophiliser capable of producing up to one million vials per year. Phase IB focuses on bioconjugate manufacturing, with reactors at 200 L and 500 L and both clinical- and commercial-scale lyophilisation lines enabling annual output of up to two million vials.
“The launch of our Fengxian Base marks a strategic milestone in AsymBio’s global expansion. The Jinshan and Fengxian facilities enhances production capacity and strengthens supply chain resilience for clients.”
Rui Yang, CEO of AsymBio
AsymBio stated that the site operates under a quality management system designed to meet the expectations of major global regulatory agencies. The facility incorporates advanced biomanufacturing technology intended to reduce costs and offer more flexible production options compared to traditional stainless-steel systems, while aligning with Asymchem’s ESG and EHS principles.
